Oral semaglutide reduces cardiovascular events by 14% at four years - report from ACC.25

Darren K. McGuire explains people taking an oral formulation of semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke after an average follow-up of four years, according to a study presented at the American College of Cardiology’s Annual Scientific Session. Video: https://medicaldigest.org/scientific-contents/interview:oral-semaglutide-reduces-cardiovascular-events-14-four-years